Applicant screening
StarMap OS scores every applicant against the seven success factors before selection. You see structural adoption risk next to the pitch score, not instead of it.
MedTech accelerator screening: stop accelerating ventures clinics will never adopt.
StarMap® gives accelerators a structured, physician-led way to score clinical credibility, adoption friction and real-world scalability across a whole cohort. Before selection, not after demo day.
Programs select on pitch quality and enthusiasm. Clinics select on fit. Accelerated or not,
75%
of venture-backed MedTech startups never return the investment.
Sources: Nelson (2025), MD+DI; TTi Health Research.
The enemy has a name
Approval Theater, at cohort scale.
Every cohort has one: the team with the CE mark, the pilot letter of intent and the polished deck that still never gets used on a ward. Programs celebrate the milestones. Clinicians don't. The gap between the two is where your credibility with clinical partners and follow-on investors quietly erodes.
Approval is the starting line. Adoption is the goal.
What you get
Three things a pitch deck cannot tell you.
StarMap looks at the same teams your jury sees and answers a different question: will this be adopted in clinical routine, and what has to change so it is?
Cohort diagnostics
Each admitted team gets a StarMap Discovery: blind spots, priorities and a roadmap that survives contact with a hospital. Delivered in batch, reviewed by EvoMed's practicing physicians.
Investor-grade evidence
By demo day every team can show clinical adoption logic that holds up in due diligence, in a format the investors in the room already trust.
How a pilot cohort runs
One cohort. Agreed metrics. Then you decide.
We don't ask for a program-wide commitment. We ask for one cohort and a number to be measured against.
-
Step 1
Scope
One call to agree cohort size, timing and the metrics that count: selection accuracy, adoption evidence at demo day, follow-on funding.
-
Step 2
Screen
Applicants complete the StarMap assessment. StarMap OS scores them, a physician cross-checks, your committee gets the ranked view.
-
Step 3
Diagnose
Every admitted team gets a Discovery and physician-led clinical adoption sessions inside your curriculum.
-
Step 4
Report
An outcome report at demo day. Continuation only if the numbers justify it. Either way you keep the screened cohort and the report.
Pilot cohort pricing
A setup fee, plus a fee per startup.
Transparent by design: one fixed amount to set the program up, one amount per startup screened and diagnosed. No retainer, no continuation obligation. The numbers depend on cohort size and application volume, so we quote them in the screening call.
Setup feeProgram setup: scoping call, metric definition, StarMap OS configured for your application flow, program-team onboarding.
Fee per startupPer admitted startup: StarMap assessment, StarMap OS scoring, physician cross-check, written Discovery, cohort view.
Live, not planned
Already running at Futury.
StarMap OS is scoring the Life Science Bootcamp cohort at Futury, the Frankfurt-based startup accelerator. The first startups have been scored, the rest of the cohort is in progress, and every score is cross-checked by EvoMed's practicing physicians before it reaches the program team. This is the reference case for the pilot cohort model.
Applicant scoring across all seven success factors
Physician cross-check on every score
Cohort-level view for the program team
Documented, not claimed
What teams say after a Discovery.
The same diagnosis your cohort gets, in the words of founders and operators who went through it.
"The most eye-opening insight was realizing how crucial technical integration will be, and which metrics I need to track as soon as I start working with clinics. I now have a clear view of the immediate, mid-term, and long-term steps."
Natalia TarasovaFounder, Intimka
"EvoMed Consulting didn't just advise us on individual questions, they guide us through complexity. Dr. Havkic helped us understand where clinical reality, regulation, and reimbursement truly intersect, and how to make the right decisions at each step. That guidance gave us clarity, confidence, and a much smoother path to adoption."
Pierre LangeGeneral Manager, OxyCare
Questions we get asked
In plain terms.
How does StarMap fit into an existing accelerator program?
It slots in at two points: before selection, where StarMap OS scores applicants against the seven success factors next to your usual pitch scoring, and during the program, where each admitted team gets a StarMap Discovery and physician-led clinical adoption sessions. Your mentors, jury and curriculum stay as they are.
What does a pilot cohort involve?
One cohort, agreed metrics, no continuation obligation. We screen the applicants, run Discovery for the admitted teams, and deliver an outcome report at demo day. If the numbers justify it, we continue. If not, you keep the report and the screened cohort.
Can StarMap OS score applicants before we select them?
Yes. That is its primary use for accelerators. Applicants complete a structured StarMap assessment, StarMap OS scores it across the seven success factors, and a physician cross-checks every score before it reaches your selection committee.
Does StarMap replace our mentors and jury?
No. It gives them something they usually don't have: a structured, clinically grounded view of adoption risk per team. Mentors coach better when they know which success factor is the real bottleneck.
Is Futury really using this today?
Yes. StarMap OS is scoring the Life Science Bootcamp cohort at Futury. The first startups have been scored and the rest of the cohort is in progress.
Pilot cohort
Run one cohort with us. Then decide.
A screening call clarifies whether your program and StarMap fit. If they don't, we say so.
Companies, clinics and programs we have worked with
